---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-25-000036"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:18:41.977763+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AbbVie Q2 adjusted EPS $2.97 (+12.1%); raises FY 2025 guidance to $11.88-$12.08

## Summary
- Q2 GAAP EPS $0.52 (down 32.5%); adjusted EPS $2.97 (+12.1%); revenue $15.423B (+6.6%).
- Immunology revenue $7.631B (+9.5%); Skyrizi $4.423B (+62.2%), Rinvoq $2.028B (+41.8%), Humira $1.180B (-58.1%).
- FY 2025 adjusted EPS guidance raised from $11.67-$11.87 to $11.88-$12.08; includes $0.55 IPR&D impact.
- Agreed to acquire Capstan Therapeutics (anti-CD19 CAR-T for autoimmune diseases); terms not disclosed.
- FDA approved Rinvoq for giant cell arteritis; Emrelis accelerated approval for c-Met high NSCLC.

## SEC filing metadata
- accession: 0001551152-25-000036
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/0001551152-25-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/abbv-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-25-000036
- JSON: https://secwatch.observer/filing/0001551152-25-000036.json
- Plain text: https://secwatch.observer/filing/0001551152-25-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.